Glenmark Pharmaceuticals Ltd (GLENMARK) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Glenmark Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Intimation of Earnings Call
Intimation · 06 Nov 2026, 8:30 am
Glenmark Pharmaceuticals Schedules Q2 FY27 Earnings Call for November 2026 Glenmark Pharmaceuticals Limited has scheduled its earnings conference call on 6th Nov'26 from 8:30 am to 9:30 am IST to discuss the unaudited financial results for the quarter ended 30th Sep'26 (Q2 FY27). Universal dial-in numbers include +91 22 6280 1298 and +91 22 7115 8199, alongside international toll-free access for the USA, UK, Singapore, and Hong Kong.
Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the Unaudited Financial ....
Intimation · 05 Nov 2026, 5:30 am
Glenmark Pharmaceuticals Schedules Board Meeting for Q2 FY27 Results Glenmark Pharmaceuticals Limited will hold a Board of Directors meeting on 5th Nov'26 to consider and approve its standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. Consequently, the trading window for designated persons and insiders, which closed on 1st Oct'26, will remain shut until 7th Nov'26 and reopen on 8th Nov'26, in compliance with SEBI insider trading regulations.
GLENMARK PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 05 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 05 Nov 2026, 5:30 am
Glenmark Therapeutics Inc. USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)
Press Release · 06 Oct 2026, 2:09 pm
Glenmark Launches Adapalene Gel USP 0.1% OTC Pump Packs in US Glenmark Therapeutics Inc., USA launched Adapalene Gel USP, 0.1% (OTC) in new pump packs, expanding its US dermatology portfolio. The product is comparable to the active ingredient of Differin Gel, 0.1%. According to Nielsen syndicated data for the 52-week period ending 5th Sep'26, the Differin Gel, 0.1% (OTC) market generated annual sales of approximately $45.8 million. The launch provides a convenient dispensing format available in 15 g and 45 g pack sizes across major retail platforms, enhancing Glenmark's OTC presence.
Glenmark Pharmaceuticals receives Establishment Inspection Report (EIS) from U.S. FDA for its Goa facility with VAI classification
Press Release · 23 Sept 2026, 2:16 pm
Glenmark Receives U.S. FDA EIR with VAI Status for Goa Facility Glenmark Pharmaceuticals Ltd announced on 23rd Sep'26 that it received the Establishment Inspection Report (EIR) from the U.S. FDA for its formulations manufacturing facility in Goa, India. The regulator classified the inspection outcome as Voluntary Action Indicated (VAI), successfully closing the audit conducted between 22nd Jun'26 and 30th Jun'26.
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst/ Institutional Investor Meetings
Intimation · 21 Sept 2026, 8:28 pm
Glenmark Pharmaceuticals to Attend PL Capital Emerging Titans Conference Glenmark Pharmaceuticals Ltd. announced under Regulation 30 of SEBI LODR that it will participate in the PL Capital - Emerging Titans 2026 Conference on 29th Sep'26 in Mumbai. The physical event will comprise both group and one-on-one institutional investor and analyst interactions. The company confirmed that no unpublished price sensitive information (UPSI) will be shared during the scheduled meetings.
Report of Scrutinizer is enclosed
Annual General Meeting · 12 Sept 2026, 12:27 am
Glenmark Pharmaceuticals Shareholders Approve All Resolutions at 48th AGM Glenmark Pharmaceuticals Limited announced the conclusion and voting results of its 48th AGM held on 11th Sep'26. Shareholders approved all ordinary and special resolutions with requisite majorities, including the adoption of standalone and consolidated financial statements for the fiscal year ended 31st Mar'26. Members approved a dividend of Rs. 2.50 per equity share with 99.9998% votes in favor, the re-appointment of Non-Executive Director Mrs. Blanche Saldanha (99.7725% in favor), and the ratification of Cost Auditor remuneration for the financial year ending 31st Mar'27.
Proceedings of the 48th AGM of the Company is enclosed
Annual General Meeting · 12 Sept 2026, 12:24 am
Glenmark expands Global Respiratory Innovation Footprint with RYALTRIS launch in Brazil
Press Release · 11 Sept 2026, 2:20 pm
Glenmark Expands Respiratory Footprint with RYALTRIS Launch in Brazil Glenmark Specialty S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., launched RYALTRIS Nasal Spray in Brazil on 11th Sep'26. Following ANVISA regulatory approval, it becomes Brazil's first olopatadine-containing intranasal combination therapy, treating moderate to severe allergic rhinitis in patients aged 12 and older. The launch targets a market where allergic rhinitis affects 20–30% of the population (40–60 million people). RYALTRIS, Glenmark's flagship globally commercialized branded innovative product, is currently approved in 57 markets worldwide, including the US, EU, UK, and China.
Please find enclosed rating rationale issued by India Ratings and Research
Others (Uncategorized) · 11 Sept 2026, 2:15 pm
India Ratings Upgrades Glenmark Pharmaceuticals’ Long-Term Bank Loans to 'IND AA+'/Stable India Ratings upgraded Glenmark Pharmaceuticals Ltd’s long-term bank loans to ‘IND AA+’/Stable from ‘IND AA’ on 10th Sep'26, driven by balance sheet deleveraging and reduced innovation funding needs following subsidiary IGI's USD700 million ISB 2001 licensing deal with AbbVie. Glenmark recognized USD560 million in FY26, enabling zero gross debt, negative net adjusted leverage of -0.13x, and FY26 EBITDA margin expansion to 26.9%. Management targets FY27 revenue of INR170 billion–INR180 billion and 21%–22% EBITDA margins, supported by Ryaltris expansion and US recovery.
Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy ....
Press Release · 21 Aug 2026, 2:22 pm
Glenmark Launches Calcium Gluconate Injection in the US Glenmark Pharmaceuticals announced on 21st Aug'26 the US launch of its Calcium Gluconate Injection USP. The product is a generic, bioequivalent version of Fresenius Kabi's drug. According to IQVIA data, the total addressable market for this injection achieved annual sales of approximately $69.9 million for the 12-month period ending Jun'26. This launch is a key step in strengthening Glenmark's US injectables business and expanding its hospital portfolio, reflecting a strategy focused on differentiated and sustainable institutional products.
Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray
Press Release · 20 Aug 2026, 2:23 pm
Glenmark Gets US FDA Nod for Generic Flonase Nasal Spray Glenmark Pharmaceuticals announced on 20-Aug'26 its receipt of U.S. FDA approval for Fluticasone Propionate Nasal Spray USP, 0.05 mg. The product is a generic version of Haleon's Flonase® Nasal Spray and will be distributed in the U.S. by Glenmark's subsidiary. This approval targets a market with annual sales of approximately $295.2 million for the 12-month period ending Jun'26, according to IQVIA data. This development expands Glenmark's respiratory portfolio in the key U.S. market, reinforcing its presence in the therapeutic area.
Letter to Shareholders whose email address are not registered providing the web link of Annual Report
Annual Report · 14 Aug 2026, 3:06 am
Please find attached Business Responsibility and Sustainability Reporting for Financial Year 2025-26
Others (Uncategorized) · 14 Aug 2026, 1:55 am
Glenmark FY26 Sustainability Report: Rising Costs and Stable ESG Metrics Glenmark’s FY26 standalone turnover reached INR 84,400.99 million, with exports contributing 57.99%. The pharmaceutical segment, its sole activity, operates in over 80 countries. Employee turnover increased to 16% in FY26 from 15% in FY25. Accounts payable days rose to 292 from 275. Customer complaints increased to 4,879 from 3,717 YoY. Environmentally, total energy consumption rose to 5.84M GJ from 5.70M GJ, while total water consumption increased to 5,140,250 KL from 5,073,020 KL. Scope 1 and 2 GHG emissions were 84,967 tCO2e.
Please find attached Notice convening the 48th Annual General Meeting and the Integrated Annual Report including BRSR for the Financial Year 2025-26.
Others (Uncategorized) · 14 Aug 2026, 1:41 am
Please find attached Notice of 48th Annual General Meeting for the Financial Year 2025-26
Annual General Meeting · 14 Aug 2026, 1:25 am
Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015
Others (Uncategorized) · 12 Aug 2026, 4:20 am
Glenmark Settles US Antitrust Litigation with Humana for $15.28 Million Glenmark Pharmaceuticals announced on 11 Aug '26 its US subsidiary has settled litigation with Humana for $15.28 million. The lawsuit involved allegations of price-fixing and anti-competitive conduct for generic drugs. Glenmark USA denies all allegations, and the settlement avoids any admission of wrongdoing. The payment, including interest, will be made in two installments and has already been provided for in the company's financials. Glenmark stated the settlement will not have a significant financial impact, resolving a key litigation overhang.
Intimation of Allotment of shares under the Employee Stock Option Plan 2016
Others (Uncategorized) · 10 Aug 2026, 8:38 pm
Glenmark Allots 23,863 Equity Shares Under ESOP 2016 Glenmark Pharmaceuticals allotted 23,863 new equity shares on 10 Aug'26 under its ESOP 2016 plan. The shares, with a face value of Re. 1, were issued at an exercise price of Rs. 600 per share, including a premium of Rs. 599. This allotment increases the company's paid-up share capital from Rs. 28,22,00,809 to Rs. 28,22,24,672. The total number of issued shares now stands at 28,22,24,672. The newly issued shares rank pari passu with existing equity shares.
Intimation of Schedule of Analyst / Institutional Investor Meetings
Intimation · 07 Aug 2026, 8:22 pm
Glenmark Pharma Announces Aug-Sep'26 Investor Meeting Schedule Glenmark Pharmaceuticals announced its schedule for analyst and investor meetings. The company will participate in four Mumbai-based conferences: Emkay Confluence on 12-Aug'26, Motilal Oswal's 22nd Annual Investor Conference on 17-Aug'26, Elara India Dialogue on 01-Sep'26, and Kotak Healthcare Forum on 17-Sep'26. All meetings will be physical and may include both group and one-on-one sessions. Glenmark stated no Unpublished Price Sensitive Information (UPSI) will be disclosed. The schedule is subject to change.
Transcript of the Earnings Call
Transcript · 05 Aug 2026, 9:38 pm
Audio recording of Q1 FY 2026-27 Earnings Call held on August 03, 2026
Audio / Video · 03 Aug 2026, 10:00 pm
Glenmark Publishes Q1 FY27 Earnings Call Audio Recording Glenmark Pharmaceuticals has uploaded the audio recording of its Q1 FY 2026-27 earnings call, held on 03 Aug '26. The company confirmed the upload via an exchange filing, making the discussion on its quarterly performance and outlook accessible to investors. The recording is available on the company's website as per SEBI regulations.
Investor Presentation - Q1 FY 26-27
Investor Presentation · 01 Aug 2026, 12:49 am
Glenmark Reports Strong Q1 FY27 Results Driven by Broad-Based Growth Glenmark reported strong Q1 FY27 results, with consolidated revenue growing 23.1% YoY to Rs. 40,185 million. Growth was broad-based, led by North America (+41.1%), Emerging Markets (+27.7%), India (+15.5%), and Europe (+11.9%). North America's performance was boosted by new launches, including a first generic FloVent with 180-day exclusivity. Consolidated EBITDA stood at Rs. 8,048 million with a margin of 20.03%, while PAT reached Rs. 4,828 million, representing an 11.8% margin. Key brands RYALTRIS and WINLEVI continue to expand globally.
Please find attached Press Release and Management Discussion & Analysis for the first quarter ended June 30, 2026
Press Release · 01 Aug 2026, 12:42 am
Glenmark Reports Strong Q1 FY27 with Broad-Based Growth Across Key Markets Glenmark reported Q1 FY27 consolidated revenue of Rs. 40,185 million, up 23.1% YoY, driven by strong performance across all key markets. EBITDA grew 38.6% YoY to Rs. 8,048 million, with a margin of 20.03%. Profit After Tax (PAT) stood at Rs. 4,828 million, a PAT margin of 11.8%. Growth was led by North America (+41.1% YoY), Emerging Markets (+27.7% YoY), and India Formulations (+15.5% YoY). The North America core business, excluding out-licensing income, grew 19.8% YoY.
Please find attached Company''s officials authorised for the purpose of determining materiality of an event or information and making disclosures to the Stock Exchanges
Others (Uncategorized) · 01 Aug 2026, 12:31 am
Glenmark Lists Officials Authorized for Materiality Disclosures Glenmark Pharmaceuticals disclosed its list of officials authorized to determine the materiality of events and make disclosures to exchanges, per SEBI regulations. The Board approved amendments to its disclosure policy on 31 Jul'26. The authorized personnel include Chairman & MD Glenn Saldanha, Executive Director & Global CFO Anurag Mantri, Executive Director of Corporate Services Cherylann Pinto, and Company Secretary Rashmi Khandelwal. This update aligns with Regulation 30(5) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.